Jaspreet Singh Sandhu, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Incontinence | 23 | 2024 | 490 | 5.560 |
Why?
|
Prostatectomy | 37 | 2024 | 1785 | 5.060 |
Why?
|
Urinary Sphincter, Artificial | 11 | 2018 | 24 | 3.700 |
Why?
|
Urethra | 14 | 2023 | 406 | 3.100 |
Why?
|
Urinary Diversion | 7 | 2024 | 134 | 3.030 |
Why?
|
Prostatic Hyperplasia | 9 | 2023 | 514 | 2.610 |
Why?
|
Transurethral Resection of Prostate | 5 | 2023 | 77 | 2.490 |
Why?
|
Urinary Bladder, Overactive | 5 | 2021 | 117 | 2.270 |
Why?
|
Cystectomy | 10 | 2024 | 603 | 2.210 |
Why?
|
Urology | 8 | 2021 | 384 | 2.200 |
Why?
|
Urinary Incontinence, Stress | 8 | 2019 | 180 | 2.100 |
Why?
|
Laser Therapy | 7 | 2023 | 1108 | 1.950 |
Why?
|
Prostatic Neoplasms | 30 | 2023 | 11094 | 1.850 |
Why?
|
Ureter | 4 | 2021 | 364 | 1.790 |
Why?
|
Urologic Surgical Procedures, Male | 7 | 2019 | 79 | 1.590 |
Why?
|
Urinary Bladder Neoplasms | 10 | 2024 | 2186 | 1.510 |
Why?
|
Urethral Stricture | 4 | 2014 | 50 | 1.380 |
Why?
|
Pelvic Neoplasms | 2 | 2021 | 249 | 1.270 |
Why?
|
Urodynamics | 9 | 2017 | 349 | 1.270 |
Why?
|
Postoperative Complications | 17 | 2024 | 15831 | 1.220 |
Why?
|
Urinary Bladder | 5 | 2021 | 1155 | 1.130 |
Why?
|
Urologic Surgical Procedures | 6 | 2018 | 281 | 1.070 |
Why?
|
Prostatitis | 3 | 2011 | 102 | 0.980 |
Why?
|
Urination Disorders | 3 | 2018 | 236 | 0.960 |
Why?
|
Erectile Dysfunction | 8 | 2021 | 437 | 0.950 |
Why?
|
Pelvic Exenteration | 4 | 2024 | 22 | 0.870 |
Why?
|
Recovery of Function | 8 | 2023 | 2978 | 0.820 |
Why?
|
Nocturia | 1 | 2021 | 18 | 0.770 |
Why?
|
Cystostomy | 1 | 2021 | 25 | 0.770 |
Why?
|
Suburethral Slings | 3 | 2019 | 69 | 0.750 |
Why?
|
Pelvic Floor | 3 | 2012 | 138 | 0.720 |
Why?
|
Certification | 3 | 2012 | 420 | 0.700 |
Why?
|
Replantation | 1 | 2021 | 145 | 0.700 |
Why?
|
Prostatism | 1 | 2019 | 16 | 0.670 |
Why?
|
Prostate-Specific Antigen | 6 | 2012 | 2463 | 0.660 |
Why?
|
Ileum | 2 | 2020 | 558 | 0.660 |
Why?
|
Prostatic Diseases | 1 | 2019 | 55 | 0.650 |
Why?
|
Surgically-Created Structures | 1 | 2018 | 9 | 0.610 |
Why?
|
Penile Erection | 2 | 2015 | 100 | 0.610 |
Why?
|
Pelvis | 3 | 2024 | 737 | 0.580 |
Why?
|
Implantable Neurostimulators | 1 | 2018 | 75 | 0.580 |
Why?
|
Hypogonadism | 1 | 2023 | 802 | 0.550 |
Why?
|
Hematoma | 1 | 2021 | 766 | 0.540 |
Why?
|
Dissection | 1 | 2018 | 298 | 0.540 |
Why?
|
Watchful Waiting | 1 | 2021 | 492 | 0.540 |
Why?
|
Sacrum | 1 | 2018 | 273 | 0.530 |
Why?
|
Connective Tissue | 1 | 2018 | 425 | 0.520 |
Why?
|
Male | 79 | 2024 | 364154 | 0.490 |
Why?
|
Electric Stimulation Therapy | 2 | 2018 | 635 | 0.470 |
Why?
|
Prosthesis Implantation | 1 | 2018 | 594 | 0.440 |
Why?
|
Nomograms | 2 | 2015 | 236 | 0.440 |
Why?
|
Directive Counseling | 1 | 2014 | 171 | 0.410 |
Why?
|
Urinary Bladder Fistula | 1 | 2012 | 10 | 0.410 |
Why?
|
Penile Implantation | 2 | 2021 | 11 | 0.390 |
Why?
|
Pelvic Organ Prolapse | 1 | 2013 | 116 | 0.390 |
Why?
|
Cholesterol, HDL | 1 | 2018 | 1814 | 0.390 |
Why?
|
Penile Prosthesis | 2 | 2021 | 32 | 0.390 |
Why?
|
Private Practice | 1 | 2012 | 154 | 0.380 |
Why?
|
Humans | 92 | 2024 | 766812 | 0.370 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2011 | 82 | 0.360 |
Why?
|
Middle Aged | 42 | 2024 | 223267 | 0.350 |
Why?
|
Cystoscopy | 3 | 2015 | 128 | 0.340 |
Why?
|
Professional Practice | 1 | 2012 | 314 | 0.340 |
Why?
|
Urinary Catheterization | 1 | 2011 | 195 | 0.340 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3692 | 0.330 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 594 | 0.330 |
Why?
|
Aged | 35 | 2024 | 171344 | 0.330 |
Why?
|
Learning Curve | 1 | 2011 | 232 | 0.320 |
Why?
|
Prosthesis Failure | 1 | 2014 | 1208 | 0.310 |
Why?
|
Genital Neoplasms, Female | 3 | 2024 | 534 | 0.310 |
Why?
|
Stents | 1 | 2020 | 3193 | 0.300 |
Why?
|
Practice Guidelines as Topic | 2 | 2023 | 7430 | 0.290 |
Why?
|
Retrospective Studies | 23 | 2024 | 81657 | 0.280 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 1931 | 0.270 |
Why?
|
Anastomosis, Surgical | 3 | 2018 | 992 | 0.270 |
Why?
|
Prostate | 4 | 2023 | 1760 | 0.260 |
Why?
|
Androgen Antagonists | 3 | 2023 | 1411 | 0.250 |
Why?
|
Urinary Bladder Diseases | 2 | 2008 | 166 | 0.250 |
Why?
|
Iodine Radioisotopes | 1 | 2009 | 1030 | 0.250 |
Why?
|
Video Recording | 1 | 2011 | 977 | 0.250 |
Why?
|
Urinary Tract | 2 | 2019 | 305 | 0.250 |
Why?
|
Robotics | 1 | 2012 | 807 | 0.250 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2005 | 21 | 0.240 |
Why?
|
Brachytherapy | 2 | 2010 | 1221 | 0.240 |
Why?
|
Salvage Therapy | 3 | 2021 | 1274 | 0.240 |
Why?
|
Cholesterol | 3 | 2020 | 2904 | 0.240 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2005 | 171 | 0.230 |
Why?
|
Electrocoagulation | 2 | 2015 | 156 | 0.230 |
Why?
|
Physicians | 2 | 2012 | 4591 | 0.230 |
Why?
|
Rectus Abdominis | 1 | 2024 | 101 | 0.220 |
Why?
|
Treatment Outcome | 19 | 2023 | 65286 | 0.220 |
Why?
|
Finasteride | 1 | 2004 | 86 | 0.220 |
Why?
|
Muscle, Skeletal | 1 | 2018 | 4968 | 0.210 |
Why?
|
Endoscopy | 2 | 2012 | 1854 | 0.210 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2004 | 112 | 0.210 |
Why?
|
Laparoscopy | 5 | 2021 | 2038 | 0.200 |
Why?
|
Urinary Retention | 2 | 2017 | 100 | 0.190 |
Why?
|
Vaginal Neoplasms | 1 | 2022 | 105 | 0.190 |
Why?
|
Urinary Reservoirs, Continent | 1 | 2021 | 29 | 0.190 |
Why?
|
Membrane Proteins | 1 | 2018 | 7869 | 0.190 |
Why?
|
Constriction, Pathologic | 2 | 2018 | 1104 | 0.190 |
Why?
|
Hematuria | 1 | 2002 | 232 | 0.180 |
Why?
|
Carcinoma in Situ | 1 | 2006 | 784 | 0.170 |
Why?
|
Patient Satisfaction | 1 | 2012 | 3485 | 0.170 |
Why?
|
Intraoperative Period | 1 | 2020 | 512 | 0.160 |
Why?
|
Cadaver | 2 | 2021 | 1362 | 0.150 |
Why?
|
Sterols | 1 | 2018 | 63 | 0.150 |
Why?
|
Urethral Diseases | 1 | 2018 | 52 | 0.150 |
Why?
|
Color | 1 | 2019 | 297 | 0.150 |
Why?
|
Time Factors | 7 | 2021 | 40149 | 0.140 |
Why?
|
Prostheses and Implants | 1 | 2004 | 1275 | 0.140 |
Why?
|
Education, Medical, Graduate | 1 | 2010 | 2418 | 0.140 |
Why?
|
Mitochondrial Membranes | 1 | 2018 | 185 | 0.140 |
Why?
|
Aged, 80 and over | 10 | 2021 | 59548 | 0.140 |
Why?
|
Societies, Medical | 2 | 2021 | 3957 | 0.140 |
Why?
|
Aerosols | 1 | 2020 | 634 | 0.140 |
Why?
|
Enzyme Inhibitors | 2 | 2005 | 3723 | 0.140 |
Why?
|
3T3 Cells | 1 | 2018 | 1082 | 0.140 |
Why?
|
Cricetulus | 1 | 2018 | 810 | 0.130 |
Why?
|
Incidence | 3 | 2021 | 21527 | 0.130 |
Why?
|
Logistic Models | 4 | 2012 | 13276 | 0.130 |
Why?
|
Postoperative Period | 1 | 2021 | 1824 | 0.130 |
Why?
|
United States | 10 | 2021 | 72945 | 0.130 |
Why?
|
Female | 20 | 2024 | 396532 | 0.130 |
Why?
|
Orphan Nuclear Receptors | 1 | 2016 | 63 | 0.130 |
Why?
|
CHO Cells | 1 | 2018 | 1376 | 0.130 |
Why?
|
Drainage | 1 | 2021 | 1182 | 0.130 |
Why?
|
Surgical Flaps | 1 | 2024 | 1680 | 0.130 |
Why?
|
Magnetic Resonance Imaging | 8 | 2021 | 36570 | 0.120 |
Why?
|
Clinical Competence | 1 | 2011 | 4858 | 0.120 |
Why?
|
Lumbosacral Plexus | 1 | 2015 | 53 | 0.120 |
Why?
|
Treatment Failure | 1 | 2021 | 2659 | 0.120 |
Why?
|
Reoperation | 2 | 2018 | 4325 | 0.120 |
Why?
|
Valsalva Maneuver | 1 | 2014 | 99 | 0.120 |
Why?
|
Sequence Alignment | 1 | 2018 | 2177 | 0.110 |
Why?
|
Radiotherapy | 2 | 2014 | 1497 | 0.110 |
Why?
|
Amyloidosis | 1 | 2002 | 877 | 0.110 |
Why?
|
Biological Transport | 1 | 2018 | 2083 | 0.110 |
Why?
|
Hawaii | 1 | 2013 | 101 | 0.110 |
Why?
|
Quality of Life | 4 | 2024 | 13476 | 0.110 |
Why?
|
Adenocarcinoma | 1 | 2011 | 6359 | 0.110 |
Why?
|
Exercise Therapy | 2 | 2011 | 935 | 0.110 |
Why?
|
Peritoneal Neoplasms | 1 | 2020 | 706 | 0.110 |
Why?
|
Ureteroscopes | 1 | 2013 | 22 | 0.110 |
Why?
|
Preoperative Care | 3 | 2018 | 2253 | 0.110 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2017 | 632 | 0.110 |
Why?
|
Thermogenesis | 1 | 2017 | 495 | 0.110 |
Why?
|
Hepatocytes | 1 | 2020 | 1246 | 0.100 |
Why?
|
Prosthesis-Related Infections | 1 | 2018 | 497 | 0.100 |
Why?
|
Fibrosis | 3 | 2016 | 2078 | 0.100 |
Why?
|
Preoperative Period | 1 | 2015 | 564 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7475 | 0.100 |
Why?
|
Endoplasmic Reticulum | 1 | 2018 | 1132 | 0.100 |
Why?
|
Fecal Incontinence | 1 | 2015 | 246 | 0.100 |
Why?
|
Interleukin-10 | 1 | 2017 | 1182 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2019 | 1195 | 0.100 |
Why?
|
Prognosis | 3 | 2018 | 29959 | 0.100 |
Why?
|
Lasers | 1 | 2015 | 951 | 0.090 |
Why?
|
Adult | 12 | 2024 | 223305 | 0.090 |
Why?
|
Age Factors | 3 | 2012 | 18397 | 0.090 |
Why?
|
Lasers, Solid-State | 1 | 2013 | 183 | 0.090 |
Why?
|
Adipocytes | 1 | 2017 | 1196 | 0.090 |
Why?
|
Urinary Incontinence, Urge | 1 | 2011 | 50 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9407 | 0.090 |
Why?
|
Combined Modality Therapy | 2 | 2014 | 8540 | 0.090 |
Why?
|
Electrodes, Implanted | 1 | 2015 | 835 | 0.090 |
Why?
|
Consensus | 2 | 2017 | 3208 | 0.090 |
Why?
|
Muscarinic Antagonists | 1 | 2011 | 135 | 0.090 |
Why?
|
Anticoagulants | 1 | 2005 | 4854 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2887 | 0.080 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2020 | 2902 | 0.080 |
Why?
|
Biofeedback, Psychology | 1 | 2010 | 117 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2662 | 0.080 |
Why?
|
Cell Membrane | 1 | 2018 | 3642 | 0.080 |
Why?
|
Obesity | 1 | 2011 | 13090 | 0.080 |
Why?
|
Organ Size | 4 | 2018 | 2262 | 0.080 |
Why?
|
Mice, Inbred C57BL | 4 | 2020 | 22351 | 0.070 |
Why?
|
Area Under Curve | 1 | 2012 | 1639 | 0.070 |
Why?
|
Lipid Metabolism | 1 | 2016 | 1895 | 0.070 |
Why?
|
Cancer Care Facilities | 1 | 2010 | 428 | 0.070 |
Why?
|
Cell Line | 2 | 2018 | 15564 | 0.070 |
Why?
|
Risk Factors | 6 | 2021 | 74889 | 0.070 |
Why?
|
Physical Therapy Modalities | 1 | 2011 | 533 | 0.070 |
Why?
|
Internationality | 1 | 2012 | 1006 | 0.070 |
Why?
|
Prospective Studies | 5 | 2021 | 54872 | 0.070 |
Why?
|
Energy Metabolism | 1 | 2017 | 2903 | 0.070 |
Why?
|
Carrier Proteins | 1 | 2018 | 4926 | 0.060 |
Why?
|
Homeostasis | 1 | 2016 | 3343 | 0.060 |
Why?
|
SEER Program | 1 | 2010 | 1444 | 0.060 |
Why?
|
Palliative Care | 1 | 2020 | 3640 | 0.060 |
Why?
|
Hypertension, Renovascular | 1 | 2005 | 115 | 0.060 |
Why?
|
Azasteroids | 1 | 2004 | 37 | 0.060 |
Why?
|
Hematocrit | 1 | 2005 | 622 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2010 | 3431 | 0.050 |
Why?
|
Kidney Pelvis | 1 | 2005 | 191 | 0.050 |
Why?
|
Disease Management | 1 | 2014 | 2533 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2021 | 39312 | 0.050 |
Why?
|
Titanium | 1 | 2004 | 494 | 0.050 |
Why?
|
Pubic Bone | 1 | 2021 | 31 | 0.050 |
Why?
|
Serum Amyloid A Protein | 1 | 2002 | 128 | 0.050 |
Why?
|
Survival Analysis | 2 | 2022 | 10101 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 10384 | 0.050 |
Why?
|
Phosphates | 1 | 2004 | 763 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 1062 | 0.050 |
Why?
|
Instillation, Drug | 1 | 2020 | 32 | 0.040 |
Why?
|
Comorbidity | 2 | 2012 | 10580 | 0.040 |
Why?
|
Nephrectomy | 1 | 2005 | 928 | 0.040 |
Why?
|
Animals | 6 | 2020 | 168939 | 0.040 |
Why?
|
Body Image | 1 | 2024 | 645 | 0.040 |
Why?
|
Models, Statistical | 1 | 2014 | 5092 | 0.040 |
Why?
|
Chronic Disease | 2 | 2017 | 9358 | 0.040 |
Why?
|
Mice | 4 | 2020 | 81898 | 0.040 |
Why?
|
General Surgery | 1 | 2010 | 1720 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2010 | 5306 | 0.040 |
Why?
|
Activating Transcription Factors | 1 | 2017 | 30 | 0.040 |
Why?
|
Cohort Studies | 2 | 2018 | 41706 | 0.040 |
Why?
|
Supine Position | 1 | 2018 | 208 | 0.040 |
Why?
|
CCAAT-Enhancer-Binding Protein-beta | 1 | 2017 | 102 | 0.040 |
Why?
|
Social Behavior | 1 | 2024 | 1147 | 0.040 |
Why?
|
Body Mass Index | 1 | 2015 | 13050 | 0.030 |
Why?
|
Republic of Korea | 1 | 2019 | 591 | 0.030 |
Why?
|
Medicare | 1 | 2015 | 6813 | 0.030 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein Group C | 1 | 2016 | 17 | 0.030 |
Why?
|
Prevalence | 1 | 2013 | 15835 | 0.030 |
Why?
|
Sterol Regulatory Element Binding Proteins | 1 | 2016 | 25 | 0.030 |
Why?
|
Pressure | 1 | 2020 | 1172 | 0.030 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 414 | 0.030 |
Why?
|
Survival Rate | 1 | 2010 | 12826 | 0.030 |
Why?
|
Patient Positioning | 1 | 2018 | 332 | 0.030 |
Why?
|
Carbon Dioxide | 1 | 2020 | 1138 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1902 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15425 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2010 | 11218 | 0.030 |
Why?
|
Random Allocation | 1 | 2019 | 2394 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2005 | 6306 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2024 | 14762 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1656 | 0.030 |
Why?
|
Risk Assessment | 2 | 2015 | 24299 | 0.030 |
Why?
|
Hemorrhage | 1 | 2005 | 3464 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2020 | 18986 | 0.030 |
Why?
|
Doxorubicin | 1 | 2020 | 2229 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2024 | 2979 | 0.030 |
Why?
|
Disease Progression | 1 | 2010 | 13642 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2006 | 12064 | 0.030 |
Why?
|
Markov Chains | 1 | 2015 | 974 | 0.020 |
Why?
|
Muscle, Smooth | 1 | 2015 | 930 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2015 | 1615 | 0.020 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2015 | 452 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4252 | 0.020 |
Why?
|
Ligands | 1 | 2016 | 3274 | 0.020 |
Why?
|
Dietary Fats | 1 | 2016 | 2001 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2005 | 15912 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9546 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3610 | 0.020 |
Why?
|
Ultrasonography | 1 | 2018 | 5990 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6514 | 0.010 |
Why?
|
Self Report | 1 | 2015 | 3771 | 0.010 |
Why?
|
Signal Transduction | 2 | 2017 | 23618 | 0.010 |
Why?
|
Rectum | 1 | 2008 | 897 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 2009 | 806 | 0.010 |
Why?
|
Renin | 1 | 2005 | 647 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1480 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5536 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12536 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7571 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 20146 | 0.010 |
Why?
|
Rectal Neoplasms | 1 | 2009 | 1183 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11876 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 11924 | 0.010 |
Why?
|
Pilot Projects | 1 | 2010 | 8728 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2009 | 2535 | 0.010 |
Why?
|
Algorithms | 1 | 2017 | 14073 | 0.010 |
Why?
|